Expansion of the Board and the company’s recent FDA Clearance marks the beginning of Orthobond’s commercialization phase

Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, today publicly announced the appointment of Eric Major as the company’s Chairman of the Board.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240710922166/en/

Eric Major (Photo: Business Wire)

"We are pleased to be expanding Orthobond’s Board of Directors with the appointment of Eric, whose vast experience in the medical device space and in driving strategic growth will be an instrumental part of Orthobond’s future,” said David Nichols, CEO of Orthobond. “The timing of Eric’s appointment is ideal given our recent announcement of our FDA clearance of the first anti-bacterial non-drug eluting solution.”

Mr. Major has over 30 years of industry experience and has a distinguished career as an entrepreneur, CEO, and Chairman. He currently serves as the Executive Chairman of the Board at Highridge Medical. His extensive background spans startup and early-stage funding, Venture Capital, Private Equity, and IPOs. His expertise extends to managing public companies, steering both public and private board governance, overseeing global operations, and formulating strategies for M&A and business integration. In his previous role as President of Stryker Spine, Mr. Major successfully led the merger of Stryker Spine’s legacy operations with K2M and growth performance. As a founder of K2M, he also held the positions of Chairman, President, and CEO, from a start-up to a publicly traded global franchise.

“Eric’s impressive career, spanning over three decades in the industry, is a testament to his extensive expertise and visionary leadership,” said Frank Cammisa, MD, Chief Emeritus of HSS Spine at Hospital for Special Surgery, CMO and Board Member at Orthobond. “His arrival marks a new chapter of innovation and growth for our company and we are thrilled to welcome such an experienced leader to help lead us toward a brighter future for Orthobond.”

“Orthobond’s antibacterial technology is a true breakthrough for patient care in the medical device space and the recent FDA clearance allows for a new and exciting chapter for the company,” said Major. “I am thrilled to be joining Orthobond at such a pivotal time. I look forward to working with an impressive Board of Directors and operating team as we enter the commercial phase for this revolutionary technology.”

Major’s addition underscores the Orthobond Board and management team’s dedication to hiring and leveraging top-tier executive and operational expertise at every level. Backed by Point72 Ventures, Orthobond has been able to establish a talented and knowledgeable board that ensures exceptional research and innovative design remain at the forefront of the company’s mission.

About Orthobond

Orthobond Corporation is a surface technology company that has developed proprietary antibacterial surfaces with broad applications in multiple industries such as medical device, commercial, industrial, automotive, and beyond. Orthobond is the first company to utilize surface modifications that can be permanently bound to any surface, killing bacteria by mechanically rupturing pathogens without using eluting antibiotics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710922166/en/